DouglasBoyerMuchmoreMD

Endocrinology • La Jolla, CA

Diabetes, Lipid Metabolism

VP, Endocrinolgoy Clinical Development, Halozyme Therapeutics, Inc

Join to view full profile

Dr. Muchmore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Muchmore's full profile

Already have an account?

Office
7037 Via Valverde
La Jolla, CA 92037
Phone+1 858-704-8289

Education & Training

University of California San Diego School of MedicineClass of 1975
University of Oklahoma Health Sciences CenterFellowship, Endocrinology, Diabetes, and Metabolism

Certifications & Licensure

CA State Medical License 1977 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus Start of enrollment: 2009 May 01
Completed
Phase 2
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus Start of enrollment: 2010 Aug 01
Completed
Phase 2
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Aug 01
Completed
Phase 2
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control Start of enrollment: 2017 Apr 18
Completed
Phase 2
21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus Start of enrollment: 2017 May 18
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

14 citations
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes.
David C. Klonoff, Bruce W. Bode, Nathan J. Cohen, Marc S. Penn, W. Blair Geho
Diabetes Care. 2019-09-11
8 citations
Subcutaneous Insulin Administration: Sufficient Progress or Ongoing Need?
Ronald J. Pettis, Douglas B. Muchmore, Lutz Heinemann
Journal of Diabetes Science and Technology. 2019-01-01
10 citations
Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects.
Sanna Rosengren, Jennifer Souratha, Dave Conway, Douglas B. Muchmore, Barry J. Sugarman
Biodrugs. 2018-02-01

Press Mentions

Diasome’s Liver Targeted InsulinApril 18th, 2019